ALLO
Price
$1.50
Change
-$0.01 (-0.66%)
Updated
Jul 25 closing price
Capitalization
328.1M
9 days until earnings call
ALNY
Price
$328.81
Change
+$0.81 (+0.25%)
Updated
Jul 25 closing price
Capitalization
42.87B
3 days until earnings call
Interact to see
Advertisement

ALLO vs ALNY

Header iconALLO vs ALNY Comparison
Open Charts ALLO vs ALNYBanner chart's image
Allogene Therapeutics
Price$1.50
Change-$0.01 (-0.66%)
Volume$2.79M
Capitalization328.1M
Alnylam Pharmaceuticals
Price$328.81
Change+$0.81 (+0.25%)
Volume$666.68K
Capitalization42.87B
ALLO vs ALNY Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. ALNY commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Buy and ALNY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ALLO: $1.50 vs. ALNY: $328.81)
Brand notoriety: ALLO and ALNY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 101% vs. ALNY: 76%
Market capitalization -- ALLO: $328.1M vs. ALNY: $42.87B
ALLO [@Biotechnology] is valued at $328.1M. ALNY’s [@Biotechnology] market capitalization is $42.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileALNY’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • ALNY’s FA Score: 1 green, 4 red.
According to our system of comparison, ALNY is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while ALNY’s TA Score has 3 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 5 bearish.
  • ALNY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than ALNY.

Price Growth

ALLO (@Biotechnology) experienced а +20.97% price change this week, while ALNY (@Biotechnology) price change was +2.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

ALNY is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($42.9B) has a higher market cap than ALLO($328M). ALNY YTD gains are higher at: 39.735 vs. ALLO (-29.577). ALNY has higher annual earnings (EBITDA): -152.58M vs. ALLO (-238.37M). ALNY has more cash in the bank: 2.63B vs. ALLO (280M). ALLO has less debt than ALNY: ALLO (81.3M) vs ALNY (1.3B). ALNY has higher revenues than ALLO: ALNY (2.35B) vs ALLO (0).
ALLOALNYALLO / ALNY
Capitalization328M42.9B1%
EBITDA-238.37M-152.58M156%
Gain YTD-29.57739.735-74%
P/E RatioN/AN/A-
Revenue02.35B-
Total Cash280M2.63B11%
Total Debt81.3M1.3B6%
FUNDAMENTALS RATINGS
ALLO vs ALNY: Fundamental Ratings
ALLO
ALNY
OUTLOOK RATING
1..100
5024
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
10022
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6044
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLO's Valuation (97) in the Biotechnology industry is in the same range as ALNY (99). This means that ALLO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that ALNY’s stock grew significantly faster than ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as ALNY (100). This means that ALLO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Price Growth Rating (44) in the Biotechnology industry is in the same range as ALLO (60). This means that ALNY’s stock grew similarly to ALLO’s over the last 12 months.

ALNY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that ALNY’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOALNY
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
70%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 7 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
61%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DPUKY6.72N/A
N/A
Dominos Pizza UK and IRL Plc.
FOLGF0.08N/A
N/A
Falcon Oil & Gas Ltd.
IQAIF0.02N/A
N/A
Imaging Biometrics Ltd
MINBY16.47N/A
N/A
Minebea Mitsumi Inc.
SFBQF1.50-0.05
-2.98%
Softbank Group Corp